Tracy McGregor, MD, Senior Director of Clinical Research at Alnylam Pharmaceuticals, gives an overview of primary hyperoxaluria type 1 (PH1).

As Dr. McGregor explains, PH1 is a rare genetic disease in which excessive oxalate production leads to painful and recurrent kidney stones. These recurrent stones increase the chance of hematuria, urinary tract infections, and end stage renal disease (ESRD). 

In November 2020, the U.S. Food and Drug Administration (FDA) approved lumasiran to treat PH1.

To learn more about PH1 and other rare kidney diseases, visit